Radiotherapy and Immunogenic Cell Death

Advances in understanding the mechanisms that underlie the interplay between radiation-invoked immune responses and tumor regression are underway. Emerging applications of local radiotherapy as an immunologic adjuvant have provided radiation oncologists with a method for converting malignant cells i...

Full description

Saved in:
Bibliographic Details
Published inSeminars in radiation oncology Vol. 25; no. 1; pp. 11 - 17
Main Authors Golden, Encouse B., Apetoh, Lionel
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Advances in understanding the mechanisms that underlie the interplay between radiation-invoked immune responses and tumor regression are underway. Emerging applications of local radiotherapy as an immunologic adjuvant have provided radiation oncologists with a method for converting malignant cells into endogenous anticancer vaccines. The dispersion of radiotherapy-induced immune-stimulating tumor antigens released from dying tumor cells into the surrounding milieu (known as immunogenic cell death, Fig. 1), is one such exploitable process that contributes to the propagation of antitumor immunity. Downstream components of the immune system may suppress, promote, or ambiguously affect antitumoral responses. Additionally, host, tumor, and treatment-related characteristics govern the significance of these signals, thereby dictating therapeutic outcomes. Herein, we review the process of radiotherapy-induced immunogenic cell death and its role in generating an in situ vaccine to help refine radioimmunotherapy-based protocols.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1053-4296
1532-9461
1532-9461
DOI:10.1016/j.semradonc.2014.07.005